Bloomberg -- Shortly after he became chief executive officer of Eli Lilly & Co. in April 2008, John Lechleiter, a former lab scientist, sent his senior executives a gift. It was a small digital clock counting down, second-by- second, to Oct. 23, 2011. That’s the day the drugmaker’s $5- billion-a-year schizophrenia pill, Zyprexa, goes off patent. Next to the countdown were four words: “Do what we do.”
